The FDA approved Itvisma, the first gene replacement therapy for children 2 years and older, teens, and adults with spinal muscular atrophy, a one-time treatment that replaces the SMN1 gene and demonstrated improved motor function in Phase 3 studies.
Experts counter Robert F. Kennedy Jr.’s claims about aluminum adjuvant safety, noting extensive evidence that aluminum-containing vaccines remain effective and well-validated.
Proposed cuts to the Hospital Preparedness Program may limit hospitals’ capacity to manage pandemics, natural disasters, and mass-casualty events affecting U.S. health systems.